SS
SLXN

SBI Securities’s Silexion Therapeutics SLXN Stock Holding History

SBI Securities’s Portfolio SLXN Stock Details SLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5 Hold
2
– – ﹤0.01% 3997
2026
Q1 		$26 Sell
2
-104
-98% -$1.82K ﹤0.01% 3717
2025
Q4 		$2.04K Hold
106
– – ﹤0.01% 2371
2025
Q3 		$3.6K Sell
106
-3
-3% -$249 ﹤0.01% 2188
2025
Q2 		$13.3K Hold
109
– – ﹤0.01% 1581
2025
Q1 		$18.1K Buy
+109
New +$21.6K ﹤0.01% 1373

Other funds holding SLXN

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
MA
Montag & Associates Atlanta, Georgia $2.37B AUM 28.86% 1-Year Est. Return
PK
Pflug Koory Omaha, Nebraska $250M AUM 42.29% 1-Year Est. Return

SBI Securities's SLXN Position: Q2 2026 in Review

SBI Securities held its Silexion Therapeutics (SLXN) position steady in Q2 2026 at 2 shares worth $5. The position accounts for ﹤0.01% of the portfolio, ranked #3997.

SBI Securities first reported a position in SLXN in Q1 2025 and has held it in 6 quarters since. The position peaked at $18.1K in Q1 2025. 6 funds tracked by Wall St. Rank hold SLXN as of Q2 2026.

  • SBI Securities held 2 shares of Silexion Therapeutics worth $5 as of Q2 2026.
  • SBI Securities left its Silexion Therapeutics share count unchanged in Q2 2026.
  • Silexion Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3997 holding.
  • SBI Securities first reported a position in Silexion Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • SBI Securities's Silexion Therapeutics position peaked at $18.1K in Q1 2025.
  • 6 funds tracked by Wall St. Rank held Silexion Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.